Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $625.96 million
  • Outstanding Shares: 44,552,000
Average Prices:
  • 50 Day Moving Avg: $14.37
  • 200 Day Moving Avg: $14.81
  • 52 Week Range: $9.85 - $18.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.54
  • P/E Growth: -1.28
Sales & Book Value:
  • Annual Revenue: $150.17 million
  • Price / Sales: 4.17
  • Book Value: $2.88 per share
  • Price / Book: 4.88
Profitability:
  • EBIDTA: ($4,590,000.00)
  • Net Margins: -23.07%
  • Return on Equity: -16.13%
  • Return on Assets: -9.84%
Debt:
  • Current Ratio: 3.36%
  • Quick Ratio: 3.35%
Misc:
  • Average Volume: 493,092 shs.
  • Beta: 1.42
  • Short Ratio: 3.61
 

Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Tuesday, May, 2nd. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. The business earned $37.42 million during the quarter, compared to analyst estimates of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 16.13% and a negative net margin of 23.07%. View Vanda Pharmaceuticals' Earnings History.

When will Vanda Pharmaceuticals make its next earnings announcement?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Vanda Pharmaceuticals.

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?

8 brokerages have issued 12 month target prices for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $24.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $21.25 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (9.43%), Vanguard Group Inc. (5.60%), Point72 Asset Management L.P. (5.58%), FMR LLC (3.59%), Morgan Stanley (3.58%) and State Street Corp (3.53%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Oxford Asset Management, Bogle Investment Management L P DE, Russell Investments Group Ltd., Alliancebernstein L.P., Morgan Stanley, State Street Corp and Kingdon Capital Management L.L.C.. Company insiders that have sold Vanda Pharmaceuticals stock in the last year include James E Flynn and Richard L Gulino. View Insider Buying and Selling for Vanda Pharmaceuticals.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Vanguard Group Inc., Nexthera Capital LP, Renaissance Technologies LLC, Citadel Advisors LLC, Spark Investment Management LLC and Gotham Asset Management LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vanda Pharmaceuticals stock cost?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $14.05.

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.25 (51.25% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/26/2017HC WainwrightInitiated CoverageBuy -> Buy$18.00LowView Rating Details
5/25/2017Jefferies Group LLCReiterated RatingBuy$21.00MediumView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
4/12/2017Oppenheimer Holdings Inc.Initiated CoverageOutperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/24/2016Piper Jaffray CompaniesSet Price TargetBuy$19.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017        
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.15)($0.17)
Q2 20172($0.25)($0.20)($0.23)
Q3 20172($0.19)($0.14)($0.17)
Q4 20172($0.14)($0.05)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Ownership Percentage: 8.45%
Institutional Ownership Percentage: 95.69%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.00View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
Source:
DateHeadline
americanbankingnews.com logoVanda Pharmaceuticals' (VNDA) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - May 26 at 12:58 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017
finance.yahoo.com - May 22 at 7:36 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 2:50 PM
americanbankingnews.com logo$40.3 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - May 13 at 9:00 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 11 at 10:44 AM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017
finance.yahoo.com - May 9 at 9:44 AM
americanbankingnews.com logoAnalysts Set Vanda Pharmaceuticals Inc. (VNDA) Price Target at $21.71
www.americanbankingnews.com - May 8 at 11:33 PM
bizjournals.com logoVanda Pharmaceuticals expands into cystic fibrosis, blood cancer - Washington Business Journal
www.bizjournals.com - May 6 at 3:30 PM
finance.yahoo.com logoETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 6 at 1:17 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 11:52 AM
americanbankingnews.com logoAnalysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 5 at 3:23 AM
finance.yahoo.com logoVanda Pharmaceuticals expands into cystic fibrosis, blood cancer
finance.yahoo.com - May 5 at 3:23 AM
americanbankingnews.com logoFY2020 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - May 4 at 8:04 PM
americanbankingnews.com logoFY2020 Earnings Forecast for Vanda Pharmaceuticals Inc. (VNDA) Issued By Jefferies Group
www.americanbankingnews.com - May 4 at 8:04 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Somewhat Likely to Affect Vanda Pharmaceuticals (VNDA) Stock Price
www.americanbankingnews.com - May 4 at 4:46 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 4:58 PM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:53 AM
finance.yahoo.com logoEdited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 9:53 AM
finance.yahoo.com logoInvestor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 6:37 PM
finance.yahoo.com logoVanda Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 6:37 PM
marketbeat.com logoVanda reports 1Q loss
marketbeat.com - May 2 at 6:13 PM
prnewswire.com logoVanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference - PR Newswire (press release)
www.prnewswire.com - May 2 at 8:26 AM
finance.yahoo.com logoVanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 1 at 7:38 PM
americanbankingnews.com logoVanda Pharmaceuticals (VNDA) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - May 1 at 7:10 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) to Release Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:58 AM
americanbankingnews.com logoVanda Pharmaceuticals (VNDA) Given Daily Coverage Optimism Rating of 0.26
www.americanbankingnews.com - April 27 at 11:58 AM
americanbankingnews.com logoFavorable Press Coverage Very Likely to Affect Vanda Pharmaceuticals (VNDA) Share Price
www.americanbankingnews.com - April 24 at 10:22 AM
americanbankingnews.com logoVanda Pharmaceuticals (VNDA) Receiving Somewhat Negative Press Coverage, Study Shows
www.americanbankingnews.com - April 21 at 5:53 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 20, 2017
finance.yahoo.com - April 21 at 12:45 AM
americanbankingnews.com logo-$0.13 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - April 20 at 2:58 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April 19, 2017
finance.yahoo.com - April 19 at 3:52 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Effect Vanda Pharmaceuticals (VNDA) Stock Price
www.americanbankingnews.com - April 17 at 8:54 AM
prnewswire.com logoVanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 - PR Newswire (press release)
www.prnewswire.com - April 15 at 5:56 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Unlikely to Impact Vanda Pharmaceuticals (VNDA) Stock Price
www.americanbankingnews.com - April 14 at 2:06 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) to Post Q1 2017 Earnings of ($0.18) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - April 14 at 8:08 AM
finance.yahoo.com logoVanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
finance.yahoo.com - April 13 at 11:11 PM
americanbankingnews.com logoOppenheimer Holdings Inc. Begins Coverage on Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - April 12 at 10:15 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:14 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 12:16 PM
americanbankingnews.com logoQ1 2017 Earnings Estimate for Vanda Pharmaceuticals Inc. (VNDA) Issued By Jefferies Group
www.americanbankingnews.com - April 10 at 7:02 AM
americanbankingnews.com logoJefferies Group Weighs in on Vanda Pharmaceuticals Inc.'s FY2020 Earnings (VNDA)
www.americanbankingnews.com - April 7 at 5:45 PM
streetinsider.com logoVanda Pharmaceuticals (VNDA), UCSF Enter License Agreement for CFTR Activators and Inhibitors
www.streetinsider.com - March 30 at 8:20 PM
us.rd.yahoo.com logoVanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors
us.rd.yahoo.com - March 30 at 8:20 PM
us.rd.yahoo.com logo5:43 pm Vanda Pharma entered into license agreement with UC San Francisco; will pay UCSF initial license fee of $1 mln and eligible to receive up to $46 mln
us.rd.yahoo.com - March 30 at 8:20 PM
streetinsider.com logoVanda Pharmaceuticals (VNDA), UCSF Enter License Agreement for CFTR Activators and Inhibitors - StreetInsider.com
www.streetinsider.com - March 30 at 8:16 AM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 23 at 6:57 AM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 4:21 AM

Social

Chart

Vanda Pharmaceuticals (VNDA) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff